Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
3.250
+0.170 (5.52%)
At close: Dec 8, 2025, 4:00 PM EST
3.210
-0.040 (-1.23%)
After-hours: Dec 8, 2025, 6:25 PM EST
Aditxt Employees
Aditxt had 26 employees as of December 31, 2024. The number of employees decreased by 21 or -44.68% compared to the previous year.
Employees
26
Change (1Y)
-21
Growth (1Y)
-44.68%
Revenue / Employee
$229
Profits / Employee
-$1,624,583
Market Cap
1.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26 | -21 | -44.68% |
| Dec 31, 2023 | 47 | -14 | -22.95% |
| Dec 31, 2022 | 61 | 3 | 5.17% |
| Dec 31, 2021 | 58 | 15 | 34.88% |
| Dec 31, 2020 | 43 | 41 | 2,050.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADTX News
- 20 days ago - Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing - Business Wire
- 5 weeks ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025 - Business Wire
- 6 weeks ago - Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market - Business Wire
- 7 weeks ago - Evofem Announces Voting Results from Special Meeting of Stockholders - PRNewsWire
- 3 months ago - Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms - PRNewsWire
- 3 months ago - Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting - PRNewsWire
- 3 months ago - Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030 - Business Wire
- 3 months ago - Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law - PRNewsWire